Polyfunctional HIV-specific T cells in Post-Treatment Controllers

AIDS

Volumn 30, Issue 15, 2016, Pages 2299-2302

  Samri, Assia ^a,b   Bacchus Souffan, Charlin ^a,b   Hocqueloux, Laurent ^c   Avettand Fenoel, Veronique ^e,f   Descours, Benjamin ^a,b   Theodorou, Ioannis ^a,b,g   Larsen, Martin ^a,b,g   Saez Cirion, Asier ^d   Rouzioux, Christine ^d   Autran, Brigitte ^a,b,g  

^a INSERM   (France)

^b Assistance publique Hôpitaux de Paris   (France)

^c Service d'urologie andrologie   (France)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

control; HIV; immune T cells; polyfunctional; spontaneous

Indexed keywords

GAMMA INTERFERON; HLA B35 ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; SECONDARY PREVENTION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; SECONDARY PREVENTION;

EID: 84978782641     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001195     Document Type: Article

References (22)

1. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
2. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
3. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al. Distinct genetic loci control plasma HIVRNA and cellular HIV-DNA levels in HIV-1 infection: The ANRS Genome Wide Association 01 study. PLoS One 2008; 3:e3907.
4. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999; 93:936-941.
5. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: Heterozygote advantage and BM35-CwM04 disadvantage. Science 1999; 283:1748-1752.
6. Peterson TA, Kimani J, Wachihi C, Bielawny T, Mendoza L, Thavaneswaran S, et al. HLA class I associations with rates of HIV-1 seroconversion and disease progression in the Pumwani Sex Worker Cohort. Tissue Antigens 2013; 81:93-107.
7. Antoni G, Guergnon J, Meaudre C, Samri A, Boufassa F, Goujard C, et al. MHC-driven HIV-1 control on the long run is not systematically determined at early times post HIV-1 infection. Aids 2013; 27:1707-1716.
8. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8R T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473-2485.
9. Descours B, Avettand-Fenoel V, Blanc C, Samri A, Melard A, Supervie V, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54:1495-1503.
10. Candotti D, Costagliola D, Joberty C, Bonduelle O, Rouzioux C, Autran B, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58:256-263.
11. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-180.
12. Frater J, Ewings F, Hurst J, Brown H, Robinson N, Fidler S, et al. HIV-1-specific CD4(R) responses in primary HIV-1 infection predict disease progression. AIDS 2014; 28:699-708.
13. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: Changes after antiretroviral therapy. Blood 2004; 103:966-972.
14. Le Corre N, Thibault F, Pouteil Noble C, Meiffredy V, Daoud S, Cahen R, et al. Effect of two injections of nonadjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine 2012; 30:7522-7528.
15. Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G. Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One 2012; 7:e42403.
16. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 2012; 4:123ra125.
17. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4RT cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-1922.
18. Boyd A, Almeida JR, Darrah PA, Sauce D, Seder RA, Appay V, et al. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection. PLoS One 2015; 10:e0128714.
19. Sauce D, Gorochov G, Larsen M. HIV-specific Th2 and Th17 responses predict HIV vaccine protection efficacy. Sci Rep 2016; 6:28129doi: 10.1038/srep28129.
20. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 2015; 33:610-616.
21. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
22. Scott-Algara D. Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI study. CROI 2015